EMERGING EVIDENCE THAT MAKES A BIG DIFFERENCE

Subclinical/Asymptomatic

Precision Primary Prevention
Evidence-Based Risk Enhancers

Unlike the risk factors-based scores which rely on the probabilistic calculations derived from population-based studies, cardiovascular imaging techniques allow for direct visualization and quantification of subclinical atherosclerosis for a more accurate, personalized risk assessment and treatment approach.1

A. Coronary Artery Calcium Scoring

Coronary artery calcium scoring is a non-invasive imaging test that uses a CT scanner to measure the amount of calcium in the walls of the coronary arteries.2

CAC is a reliable marker of coronary atherosclerosis and vascular age. Thus, CAC is useful for assessing risk and predicting future atherosclerotic cardiovascular disease (ASCVD) events in asymptomatic patients with no established coronary artery disease.3

The presence or absence, amount, and distribution of CAC are strong prognostic indicators that can assist physicians in reclassifying patient risk status as necessary.3

More than 50 % had been categorized as low risk just before the event (in an examination of 1,475 people who had a myocardial infarction before or at age 50).4

Many studies have revealed that many coronary events occur in people who were not previously considered high-risk, do not have known obstructive coronary artery disease, and/or have normal functional tests.4

CAC scores could be used as reliable gatekeepers for risk classification and the initiation of preventative therapies.6

In the absence of a high bleeding risk, aspirin is likely to be effective in those under the age of 70 who have a CAC ≥ , and they have an absolute net benefit from using it.7

CAC scoring is a robust marker of coronary atherosclerotic plaque burden and can be used to determine the need for and intensity of preventive therapies.8,9

Relationship between CAC score & atherosclerosis lesions in low risk patients10

Interpretation of calcium score for low-risk patients

Total CAC score is computed by summing the scores of all calcified lesions.3
Agatston score Plaque burden Probability of significant CAD
0 No plaque Very low
1-10 Minimal plaque Low
11-100 At least mild atherosclerotic plaque Mild or minimal coronary artery stenosis

B. Carotid Artery Plaque Score

If CAC scoring is inaccessible or not feasible, a carotid artery ultrasound can be used to predict CVD events by measuring carotid intima-media thickness or assessing carotid arterial plaques.11, 12

Cost-effectiveness: low-income countries can utilize arterial ultrasounds to identify at-risk individuals.11, 12

Low-income individuals are less likely to be screened for CVD or receive preventive care than high-income individuals that reside in the same country regardless of existing CVD status.11, 12

The greater benefit seen with plaque assessment compared with CIMT for risk prediction.11

Measurement of carotid intima-media thickness (CIMT), CIMT measurement identifies areas of increased carotid artery wall thickness, providing an easily accessible imaging biomarker for the classification of cardiovascular risk for individuals as well as population cohorts.10

Assessment of carotid arterial plaque, a sub-intimal process, may be more reflective of atherosclerosis, as it correlates with overall atherosclerotic burden in the coronary vascular bed. The assessment of carotid arterial plaque offers an even greater risk stratification benefit than CIMT.10

Patient profile

Hypertension
Hypertension

2x increase in death rate from IHD and other vascular causes for each 20/10 mmHg rise in BP in some age groups, starting at 115/75 mmHg.13

Dyslipidemia
Dyslipidemia

The overall reduction of about one fifth per mmol/l LDL-C reduction is translated into 25 fewer participants having major vascular events per 1000 participants without pre-existing MI or CHD at baseline.14

Association

Association of a small dose of aspirin with active antihypertensive treatment reduced the risk of acute myocardial infarction without exaggerating the risk of cerebral bleeding.15

T. is at intermediate risk, he needs CAC & CPS

Hypertension
Hypertension

2x increase in death rate from IHD and other vascular causes for each 20/10 mmHg rise in BP in some age groups, starting at 115/75 mmHg.13

Dyslipidemia
Dyslipidemia

The overall reduction of about one fifth per mmol/l LDL-C reduction is translated into 25 fewer participants having major vascular events per 1000 participants without pre-existing MI or CHD at baseline.14

Association
Diabetes

RR of ischemic heart disease death in diabetics vs. nondiabetics is 1.8 (men); RR of ischemic heart disease death in diabetics vs. nondiabetics is 3.3 (women).15

Association

The use of low-dose aspirin leads to a lower risk of serious vascular events.16

S. is at intermediate risk, she needs CAC & CPS

CAC: coronary artery calcium; CVD: cardiovascular disease; CIMT: carotid intima-media thickness; CAD: coronary artery disease; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; BP: Blood pressure; LDL-C: Low-density lipoprotein cholesterol; MI: Myocardial infarction; ASCVD: Atherosclerotic cardiovascular disease; IHD: ischemic heart disease; CHD: coronary heart disease; RR: relative risk; CPS: carotid plaque score; NNH: number needed to harm; and NN: number needed to treat.

References

  1. Weber LA, Cheezum MK, Reese JM, et al. Cardiovascular Imaging for the Primary Prevention of Atherosclerotic Cardiovascular Disease Events. Curr Cardiovasc Imaging Rep. 2015;8(9):36.
  2. Adamson PD, Newby DE. Non-invasive imaging of the coronary arteries. Eur Heart J. 2019 Aug 1;40(29):2444-2454. doi: 10.1093/eurheartj/ehy670. PMID: 30388261; PMCID: PMC6669405.
  3. Cheong BYC, Wilson JM, Spann SJ, Pettigrew RI, Preventza OA, Muthupillai R. Coronary artery calcium scoring: an evidence-based guide for primary care physicians. J Intern Med. 2021;289(3):309-324.
  4. Blaha MJ, Abdelhamid M, Santilli F, Shi Z, Sibbing D. Advanced subclinical atherosclerosis: A novel category within the cardiovascular risk continuum with distinct treatment implications. Am J Prev Cardiol. 2022;13:100456.
  5. Silverman MG, Blaha MJ, Krumholz HM, et al. Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis. Eur Heart J. 2014;35(33):2232-2241.
  6. Greenland, P., Blaha, M. J., Budoff, M. J., Erbel, R., & Watson, K. E. (2018). Coronary calcium score and cardiovascular risk. Journal of the American College of Cardiology, 72(4), 434-447.
  7. Verghese D, Manubolu S, Budoff MJ. Contemporary use of coronary artery calcium for the allocation of aspirin in light of the 2022 USPSTF guideline recommendations. Am J Prev Cardiol. 2022;12:100427.
  8. Cainzos-Achirica M, Miedema MD, McEvoy JW, et al. Coronary Artery Calcium for Personalized Allocation of Aspirin in Primary Prevention of Cardiovascular Disease in 2019: The MESA Study (Multi-Ethnic Study of Atherosclerosis). Circulation. 2020;141(19):1541-1553.
  9. Coronary Artery Calcium Scoring to Guide Prevention of ASCVD. National Lipid Association. Available at: https://www.lipid.org/nla/cac-scoring-guide-prevention-ascvd. Last accessed at: 16/4/2023.
  10. Parikh P, Shah N, Ahmed H, Schoenhagen P, Fares M. Coronary artery calcium scoring: Its practicality and clinical utility in primary care. Cleve Clin J Med. 2018;85(9):707-716.
  11. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337.
  12. Johri AM, Nambi V, Naqvi TZ, et al. Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography. J Am Soc Echocardiogr. 2020;33(8):917-933.
  13. Lewington S, Clarke R, Qizilbash N et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. The Lancet. 2002;360(9349):1903-1913.
  14. Baigent C, Keech A, Kearney P et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet. 2005;366(9493):1267-1278.
  15. Hansson L, Zanchetti A, Carruthers S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The Lancet. 1998;351(9118):1755-1762.
  16. Louise B, Marion M, Karl W et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. New England Journal of Medicine. 2018;379(16):1529-1539.